---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000037"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:38:19.788020+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Japan MHLW approves Novocure's Optune Lua for advanced NSCLC

## Summary
- Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.
- Approval based on Phase 3 LUNAR trial: median OS 13.2 vs 9.9 months (3.3-month improvement, p=0.04).
- In PD-1/PD-L1 subgroup, median OS 19.0 vs 10.8 months (8.2-month improvement, p=0.02).
- Optune Lua is a wearable TTFields device; device-related AEs were mostly grade 1-2 skin reactions.

## SEC filing metadata
- accession: 0001645113-25-000037
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000037/0001645113-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000037/nvcr-20250915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000037
- JSON: https://secwatch.observer/filing/0001645113-25-000037.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.